Drug intelligence / Profile preview

ELAPR002

Development stage: Unknown
Lead developer: Allergan
Modality: Peptides
Administration: Intradermal, Implant

Overview

ELAPR002 is a clinical-stage intradermal implant composed of recombinant human tropoelastin cross-linked with derivatized hyaluronic acid. Developed by Elastagen (acquired by Allergan, now part of AbbVie), it is designed to treat atrophic acne scars and other skin conditions by restoring the natural extracellular matrix and improving skin elasticity. The technology utilizes a proprietary platform to produce human tropoelastin, the soluble precursor of elastin, which provides the skin with its resilience and recoil properties. The product is administered as an intradermal injection to provide both immediate volume and long-term tissue repair.

Other names: cross-linked tropoelastin matrix

Targets

ELN (Elastin)

Beyond the preview

Go deeper on ELAPR002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELAPR002.

Explore the full profile